
|Videos|May 12, 2016
The Long-Term Impact of Biosimilars on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Advertisement
Grant E. Knowles, vice president of business development at Ardon Health, discusses how biosimilars may impact the high cost of specialty drugs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Long COVID and Brain Health
2
Recapping 2025 ASHP Midyear: Expanding the Pharmacist’s Role in Patient Care, Technology, and Health System Resilience
3
Expert: Why Cutting Alcohol May Enhance GLP-1 Outcomes in Patients With Obesity and Diabetes Risk
4
Radio Frequency Identification is Revolutionizing Medication Management
5
















